These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 25855484)

  • 1. Transition considerations for extended half-life factor products.
    Croteau SE; Neufeld EJ
    Haemophilia; 2015 May; 21(3):285-288. PubMed ID: 25855484
    [No Abstract]   [Full Text] [Related]  

  • 2. Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH.
    Iorio A; Blanchette V; Blatny J; Collins P; Fischer K; Neufeld E
    J Thromb Haemost; 2017 Dec; 15(12):2461-2465. PubMed ID: 29119666
    [No Abstract]   [Full Text] [Related]  

  • 3. Continuous infusion of coagulation factors: current opinion.
    Batorova A; Martinowitz U
    Curr Opin Hematol; 2006 Sep; 13(5):308-15. PubMed ID: 16888434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stretching time.
    Savage N
    Sci Am; 2015 Jan; 312(1):S8-10. PubMed ID: 25597117
    [No Abstract]   [Full Text] [Related]  

  • 5. Needles and needleless devices for infusion of anti-haemophilic factor concentrate: impact on protein structure and function.
    Prabhu S; Kazarian T; Hakobyan N; Jabbar A; Dunham T; Valentino LA
    Haemophilia; 2006 Jan; 12(1):58-61. PubMed ID: 16409176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of enhanced half-life factor VIII and IX in the treatment of haemophilia.
    Mahdi AJ; Obaji SG; Collins PW
    Br J Haematol; 2015 Jun; 169(6):768-76. PubMed ID: 25754016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia.
    Croteau SE; Cheng D; Cohen AJ; Holmes CE; Malec LM; Silvey M; Thornburg CD; Wheeler AP; Kouides PA; Raffini LJ; Neufeld EJ
    Haemophilia; 2019 Jul; 25(4):668-675. PubMed ID: 30993845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment on demand--in vivo dose finding studies.
    Escobar MA
    Haemophilia; 2003 Jul; 9(4):360-7. PubMed ID: 12828669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factor VIII and IX assays for post-infusion monitoring in hemophilia patients: Guidelines from the French BIMHO group (GFHT).
    Jeanpierre E; Pouplard C; Lasne D; Le Cam Duchez V; Eschwege V; Flaujac C; Galinat H; Harzallah I; Proulle V; Smahi M; Sobas F; Stepina N; Toulon P; Voisin S; Ternisien C; Nougier C;
    Eur J Haematol; 2020 Aug; 105(2):103-115. PubMed ID: 32277501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is haemophilia prophylaxis achievable in the context of self-sufficiency?
    Nilsson IM
    Blood Coagul Fibrinolysis; 1994 Dec; 5 Suppl 4():S71-5. PubMed ID: 7795143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of recombinant coagulation factors in treating hemophilia.
    Morfini M; Rapisarda CAP
    Expert Opin Drug Saf; 2019 Feb; 18(2):75-85. PubMed ID: 30681006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO.
    Collins P; Chalmers E; Chowdary P; Keeling D; Mathias M; O'Donnell J; Pasi KJ; Rangarajan S; Thomas A
    Haemophilia; 2016 Jul; 22(4):487-98. PubMed ID: 27311929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging drugs for hemophilia B.
    Mannucci PM; Franchini M
    Expert Opin Emerg Drugs; 2014 Sep; 19(3):407-14. PubMed ID: 25098797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis and treatment of congenital hemophilia with inhibitors a Latin American perspective.
    Pérez Bianco R; Ozelo MC; Villaça PR; Solano MH; Jimenez Cruze G; Martinez Murillo C; Garcia Chavez J; Mendoza S; Rodriguez Grecco I; Ruiz-Saez A
    Medicina (B Aires); 2008; 68(3):227-42. PubMed ID: 18689157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylaxis in children with hemophilia: is it the optimal treatment?
    Lusher JM
    Thromb Haemost; 1997 Jul; 78(1):726-9. PubMed ID: 9198246
    [No Abstract]   [Full Text] [Related]  

  • 16. Recombinant clotting factors in the treatment of hemophilia.
    Lee C
    Thromb Haemost; 1999 Aug; 82(2):516-24. PubMed ID: 10605745
    [No Abstract]   [Full Text] [Related]  

  • 17. Prophylactic infusion regimens in the management of hemophilia.
    Ljung RC
    Thromb Haemost; 1999 Aug; 82(2):525-30. PubMed ID: 10605746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging drugs for the treatment of hemophilia A and B.
    Morfini M; Zanon E
    Expert Opin Emerg Drugs; 2016 Sep; 21(3):301-13. PubMed ID: 27547884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New products for the treatment of haemophilia.
    Laffan M
    Br J Haematol; 2016 Jan; 172(1):23-31. PubMed ID: 26456702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on treatment regimens: prophylaxis versus on-demand therapy.
    Manco-Johnson MJ
    Semin Hematol; 2003 Jul; 40(3 Suppl 3):3-9. PubMed ID: 14690062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.